How has the glomerulonephritis market evolved, and where is it heading next?
The glomerulonephritis market size has grown strongly in recent years. It will grow from $11.06 billion in 2024 to $11.64 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to the rising prevalence of kidney disorders, the prevalence of infections such as post-streptococcal glomerulonephritis, the rise in research and development, the increase in the incidence of kidney failure, and the growth in awareness regarding kidney diseases.
The glomerulonephritis market size is expected to see strong growth in the next few years. It will grow to $14.14 billion in 2029 at a compound annual growth rate (CAGR) of 5.0%. The growth in the forecast period can be attributed to increasing incidences of diabetes, an aging population, increasing investments in healthcare expenditure, an increase in the number of patients on dialysis, and rising cases of autoimmune diseases. Major trends in the forecast period include the launch of new treatments and therapies, advances in diagnostic technologies, novel therapeutics and therapies, collaboration between companies, and intravenous immunoglobulin therapy.
Get Your Free Sample of The Global Glomerulonephritis Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21193&type=smp
What are the key drivers behind the rapid expansion of the glomerulonephritis market?
The rising prevalence of kidney disorders is expected to propel the growth of the glomerulonephritis market going forward. Kidney disorders refer to a range of conditions that affect the structure or function of the kidneys, leading to impaired filtration, waste removal, and fluid balance. The rising prevalence of kidney disorders is due to factors such as aging populations, rising rates of chronic diseases such as diabetes and hypertension, and lifestyle choices. Kidney disorders contribute to glomerulonephritis by triggering immune system dysfunction, chronic inflammation, or structural damage, leading to impaired kidney filtration and function. For instance, in December 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, chronic kidney disease (CKD) mortality rates increased by 4.2% in 2021 and 6.2% in 2022. In 2021–22, CKD was noted in around 2 million hospitalizations, representing 18% of all hospitalizations in Australia. Therefore, the rising prevalence of kidney disorders will drive the growth of the glomerulonephritis market.
What is the segmentation for the glomerulonephritis market?
The glomerulonephritis market covered in this report is segmented –
1) By Type: Acute Glomerulonephritis, Chronic Glomerulonephritis
2) By Diagnosis: Urine And Blood Tests, Imaging Tests, Kidney Biopsy, Other Diagnosis
3) By Treatment: Medication, Surgery, Dialysis, Other Treatments
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
5) By End-User: Hospitals, Specialty Clinics, Other End-Users
Subsegments:
1) By Acute Glomerulonephritis: Post-infectious Glomerulonephritis, IgA Nephropathy, Lupus Nephritis, Rapidly Progressive Glomerulonephritis (RPGN), Goodpasture Syndrome
2) By Chronic Glomerulonephritis: Focal Segmental Glomerulosclerosis (FSGS), Membranous Nephropathy, Minimal Change Disease, Alport Syndrome, Diabetic Nephropathy, Hypertensive Nephrosclerosis
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/glomerulonephritis-global-market-report
Who are the most influential companies in the glomerulonephritis market?
Major companies operating in the glomerulonephritis market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Asahi Kasei Medical Co. Ltd., Boehringer Ingelheim International GmbH, DaVita Inc., Biogen Inc., Merit Medical Systems Inc., Apellis Pharmaceuticals Inc., MorphoSys AG, Travere Therapeutics Inc., Vera Therapeutics Inc., Calliditas Therapeutics AB, Omeros Corporation, Otsuka Pharmaceutical Co. Ltd., Aurinia Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., NovelMed Therapeutics Inc.
What are the most influential trends expected to drive the glomerulonephritis market forward?
Major companies operating in the glomerulonephritis market are focusing on developing advanced non-immunosuppressive treatments to address unmet medical needs and improve patient outcomes. Non-immunosuppressive treatments are therapies that do not weaken or suppress the immune system, aiming to treat conditions without compromising immune function. For instance, in September 2024, Travere Therapeutics Inc., a US-based biopharmaceutical company, introduced FILSPARI (sparsentan), approved by the Food and Drug Administration (FDA) for treating IgA nephropathy, a kidney disease. The drug is the only non-immunosuppressive treatment shown to significantly slow kidney function decline in these patients. FILSPARI’s approval marks a major breakthrough in the treatment of IgA nephropathy, which is the most common type of primary glomerulonephritis. The therapy offers a new option for patients who previously had limited choices. This approval highlights Travere’s commitment to improving patient outcomes in kidney disease.
What are the major regional insights for the glomerulonephritis market, and which region holds the top position?
North America was the largest region in the glomerulonephritis market in 2024. The regions covered in the glomerulonephritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Glomerulonephritis Market Report 2025 Offer?
The glomerulonephritis market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Glomerulonephritis is a kidney disorder characterized by inflammation of the glomeruli, the tiny filters in the kidneys that remove waste and excess fluids from the blood. It can result from infections, autoimmune diseases, or other underlying conditions, leading to symptoms such as blood in urine, proteinuria, and swelling. If left untreated, it may progress to chronic kidney disease or kidney failure.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21193
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
